ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸

ORKA // Oruka Therapeutics Inc.

SPLC <GO> NASDAQ RQD COCKPIT → CIK 0000907654 ↗
Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$95.43 ▼ -1.44 (-1.49%)
MKT CAP: $6.41B • VOL: 654.4K
ORKA // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>) SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO> CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NASDAQ
ORKA // Oruka Therapeutics Inc.
GROSS MARGIN
—
OP MARGIN
-6.8%
ROIC %
-18.8%
MKT CAP
$6.41B
UPSTREAM INPUTS ──► ORKA OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO> REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO> REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX LIVE DB CROSS-COMPARISON
TICKER COMPANY LAST MKT CAP GROSS MGN OP MGN ROIC % EV/EBITDA REV YOY HEAD-TO-HEAD
ORKA ★ Oruka Therapeutics Inc. $95.43 $6.41B — -6.8% -18.8% — -4.4% SUBJECT ISSUER
LLY Eli Lilly and Company $1,417.54 $1.33T 83.6% 40.2% 32.4% 36.4x +45.5% ORKA VS LLY <GO>
JNJ Johnson & Johnson $273.20 $657.68B 67.9% 34.7% 25.5% 18.5x +6.0% ORKA VS JNJ <GO>
ABBV AbbVie Inc. $294.89 $521.11B 70.2% 24.6% 29.0% 33.3x +8.6% ORKA VS ABBV <GO>
MRK Merck & Company Inc. $149.52 $368.89B 74.8% 34.3% 20.7% 15.3x +1.3% ORKA VS MRK <GO>
UNH UnitedHealth Group Incorporated $406.97 $365.29B 88.6% 4.8% 11.5% 16.5x +6.5% ORKA VS UNH <GO>